News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 12, 2020

The Latest in Care for Suicidal Teens and Young Adults

Author(s)Shareh Ghani, MD

Dr Ghani talks on caring for teens and young adults with suicidal ideation, especially in this time of increased stressors.

Dr Ghani is Medical Director for Magellan Healthcare.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

bipolar disorder

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

ByAndrew Nguyen, MD, MSc,Ayal Schaffer, MD, FRCPC

November 26th 2025

lithium suicide bipolar major depressive disorder

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

ByKenneth J. Bender, PharmD, MA

November 26th 2025

suicide self-harm risk prediction model

Models for Self-Harm and Suicide Risk, Review With Investigator Seena Fazel, MD

BySeena Fazel, MBChB, MD, FRCPsych

November 19th 2025

chatbot AI suicide safety

Making Chatbots Safe For Suicidal Patients

ByAllen Frances, MD,Ursula Whiteside, MD

November 18th 2025

veteran

Meeting the Needs of Veteran Patients

ByEugene T. Lucas Jr, DNP, CRNP, FNP-BC, APMHNP-BC

November 11th 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

NDA Submission: Olanzapine Extended-Release Injectable Suspension for Treatment of Schizophrenia

FDA Accepts NDA for TRN-257 for Treatment of Narcolepsy and Idiopathic Hypersomnia

Transcranial Magnetic Stimulation in Sports Performance: Promise, Physiology, and Precaution

Evenamide for Treatment-Resistant Schizophrenia: Initiation of ENIGMA-TRS 2 Phase 3 Clinical Study

An Impressive Year: Looking Back on Our 40th Anniversary

© 2025 MJH Life Sciences^®

All rights reserved.